CMYA5

Summary

CMYA5 (cardiomyopathy associated 5, HGNC:14305) is a protein-coding gene on chromosome 5q14.1, encoding Cardiomyopathy-associated protein 5 (Q8N3K9). May serve as an anchoring protein that mediates the subcellular compartmentation of protein kinase A (PKA) via binding to PRKAR2A.

Predicted to enable identical protein binding activity and protein phosphatase inhibitor activity. Predicted to act upstream of or within negative regulation of calcineurin-NFAT signaling cascade and regulation of skeletal muscle adaptation. Predicted to be located in several cellular components, including costamere; perinuclear region of cytoplasm; and sarcoplasmic reticulum. Predicted to be active in cytoplasm.

Source: NCBI Gene 202333 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 717 total
• MANE Select transcript: NM_153610

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14305
Approved symbol	CMYA5
Name	cardiomyopathy associated 5
Location	5q14.1
Locus type	gene with protein product
Status	Approved
Aliases	SPRYD2, DKFZp451G223, TRIM76
Ensembl gene	ENSG00000164309
Ensembl biotype	protein_coding
OMIM	612193
Entrez	202333

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 5 protein_coding, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000446378, ENST00000505466, ENST00000506603, ENST00000856934, ENST00000940890, ENST00000940891, ENST00000940892

RefSeq mRNA: 1 — MANE Select: NM_153610 NM_153610

CCDS: CCDS47238

Canonical transcript exons

ENST00000446378 — 13 exons

Exon	Start	End
ENSE00001237325	79728915	79739403
ENSE00001704191	79689836	79690056
ENSE00001760990	79799370	79800222
ENSE00001781527	79763062	79763209
ENSE00003481027	79790970	79791069
ENSE00003523484	79793437	79793610
ENSE00003583642	79747091	79747113
ENSE00003597264	79743827	79743922
ENSE00003601340	79761811	79761957
ENSE00003608048	79745222	79745455
ENSE00003644892	79752676	79752794
ENSE00003654101	79788971	79789104
ENSE00003677029	79758753	79758902

Expression profiles

Bgee: expression breadth ubiquitous, 224 present calls, max score 99.96.

FANTOM5 (CAGE): breadth broad, TPM avg 12.1205 / max 3678.6110, expressed in 347 samples.

FANTOM5 promoters (14 alternative TSS)

Promoter ID	TPM avg	Samples expressed
57254	10.0696	300
57253	0.8801	47
57255	0.5614	66
57276	0.1620	40
57275	0.0962	24
57278	0.0683	22
57277	0.0591	22
57274	0.0567	12
57272	0.0505	19
57270	0.0500	17

Top tissues by expression

250 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tibialis anterior	UBERON:0001385	99.96	gold quality
cardiac muscle of right atrium	UBERON:0003379	99.91	gold quality
left ventricle myocardium	UBERON:0006566	99.90	gold quality
deltoid	UBERON:0001476	99.88	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	99.86	gold quality
quadriceps femoris	UBERON:0001377	99.84	gold quality
biceps brachii	UBERON:0001507	99.84	gold quality
vastus lateralis	UBERON:0001379	99.83	gold quality
skeletal muscle tissue	UBERON:0001134	99.81	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	99.81	gold quality
myocardium	UBERON:0002349	99.80	gold quality
gastrocnemius	UBERON:0001388	99.74	gold quality
hindlimb stylopod muscle	UBERON:0004252	99.67	gold quality
heart right ventricle	UBERON:0002080	99.61	gold quality
muscle of leg	UBERON:0001383	99.42	gold quality
body of tongue	UBERON:0011876	99.40	gold quality
apex of heart	UBERON:0002098	99.15	gold quality
cardiac atrium	UBERON:0002081	99.09	gold quality
right atrium auricular region	UBERON:0006631	99.03	gold quality
cardiac ventricle	UBERON:0002082	98.90	gold quality
heart left ventricle	UBERON:0002084	98.88	gold quality
muscle tissue	UBERON:0002385	97.09	gold quality
heart	UBERON:0000948	95.46	gold quality
tongue	UBERON:0001723	94.94	gold quality
vena cava	UBERON:0004087	94.19	gold quality
left ovary	UBERON:0002119	92.57	gold quality
calcaneal tendon	UBERON:0003701	90.03	gold quality
right ovary	UBERON:0002118	89.37	gold quality
ovary	UBERON:0000992	88.45	gold quality
pharyngeal mucosa	UBERON:0000355	88.26	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	12.63
E-MTAB-11268	no	4515.48

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

33 targeting CMYA5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-130B-3P	99.90	73.27	1850
HSA-MIR-301A-3P	99.90	73.15	1839
HSA-MIR-301B-3P	99.90	73.19	1836
HSA-MIR-3666	99.90	73.24	1833
HSA-MIR-4295	99.90	73.11	1838
HSA-MIR-5682	99.89	72.56	1005
HSA-MIR-4671-3P	99.88	72.46	1045
HSA-MIR-576-5P	99.84	70.46	2582
HSA-MIR-1321	99.84	65.30	1811
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-139-5P	99.80	69.50	1399
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-6513-3P	99.59	69.77	1102
HSA-MIR-6853-3P	99.36	70.79	1558
HSA-MIR-32-3P	99.36	68.20	2517
HSA-MIR-580-5P	99.28	70.94	1776
HSA-MIR-4528	99.18	69.77	1936
HSA-MIR-1178-3P	98.57	67.09	890
HSA-MIR-7156-3P	98.25	67.66	859
HSA-MIR-6748-3P	97.20	65.66	836
HSA-MIR-7161-3P	96.79	68.79	798
HSA-MIR-4280	96.44	67.69	473

Literature-anchored findings (GeneRIF, showing 15)

• Functions directly downstream of MEF2A at the costamere in striated muscle potentially playing a role in myofibrillogenesis. (PMID:16407236)
• perinuclear localization of the TRIM-like protein myospryn requires its binding partner desmin (PMID:17872945)
• Polymorphism of myospryn is associated with left ventricular hypertrophy, and an association between a Z-disc protein and cardiac adaptation in response to pressure overload. (PMID:18344630)
• Review discusses interactions that suggest myospryn is involved in two seemingly distinct processes, protein kinase A signalling and vesicular trafficking. (PMID:19140017)
• Interactions with M-band titin and calpain 3 link myospryn (CMYA5) to tibial and limb-girdle muscular dystrophies. (PMID:20634290)
• 2 SNPS in CYMA5, rs4704591 & rs10043986, are significantly associated with schizophrenia. Haplotype conditioned analyses indicated that the association signals observed at these two markers are independent. (PMID:20838396)
• This study demonstrated that the association between CMYA5 and schizophrenia in Han Chinese. (PMID:21295948)
• CMYA5 is a new potential substrate of Kcna3 in human heart (PMID:23335746)
• Association of cardiomyopathy-associated 5 (CMYA5) gene of Schizophrenia, is reported. (PMID:23528614)
• In a Han Chinese sample of schizophrenic patients, SNPs within CMYA5 were associated with the disorder. (PMID:23778016)
• meta-analysis confirming association of CMYA5 polymorphisms and schizophrenia in East Asian population. (PMID:24524722)
• Specific alleles and haplotype in the CMYA5 confer genetic risk for both schizophrenia and major depressive disorder in the Han Chinese population. (PMID:24988482)
• association between CMYA5 gene polymorphisms and schizophrenia was confirmed in Asian population. (PMID:26403435)
• The results showed that MYBPC3 25-bp deletion polymorphism was significantly associated with elevated risk of left ventricular dysfunction (LVD), while TTN 18 bp I/D, TNNT2 5 bp I/D and myospryn K2906N polymorphisms did not show any significant association with LVD. (PMID:27350668)
• meta-analysis did not provide evidence supporting a contribution of CMYA5 rs3828611 and rs4704591 to schizophrenia susceptibility in Asian populations. (PMID:28776924)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	cmya5	ENSDARG00000061379
danio_rerio	si:ch1073-398f15.1	ENSDARG00000100353
mus_musculus	Cmya5	ENSMUSG00000047419
rattus_norvegicus	Cmya5	ENSRNOG00000023803

Paralogs (3): FSD1 (ENSG00000105255), FSD1L (ENSG00000106701), FSD2 (ENSG00000186628)

Protein

Protein identifiers

Cardiomyopathy-associated protein 5 — Q8N3K9 (reviewed: Q8N3K9)

Alternative names: Dystrobrevin-binding protein 2, Genethonin-3, Myospryn, SPRY domain-containing protein 2, Tripartite motif-containing protein 76

All UniProt accessions (1): Q8N3K9

UniProt curated annotations — full annotation on UniProt →

Function. May serve as an anchoring protein that mediates the subcellular compartmentation of protein kinase A (PKA) via binding to PRKAR2A. May function as a repressor of calcineurin-mediated transcriptional activity. May attenuate calcineurin ability to induce slow-fiber gene program in muscle and may negatively modulate skeletal muscle regeneration. Plays a role in the assembly of ryanodine receptor (RYR2) clusters in striated muscle.

Subunit / interactions. Interacts with PRKAR2A. Interacts with ACTN2 and DTNBP1/dysbindin. Interacts with DES. Interacts with DMD/dystrophin. Interacts with the calcineurin catalytic subunit PPP3CA. Interacts with TTN. Interacts with CAPN3; this interaction, which results in CMYA5 proteolysis, may protect CAPN3 from autolysis. Interacts with FSD2. Identified in a complex composed of FSD2, CMYA5 and RYR2.

Subcellular location. Nucleus. Sarcoplasmic reticulum. Cytoplasm. Perinuclear region. Myofibril. Sarcomere. M line.

Tissue specificity. Expressed in skeletal muscle; at a strong level and in heart.

Post-translational modifications. Phosphorylated by PKA.

Domain organisation. Amphipathic helix regions act as an anchoring domain for PKA, and appear to be responsible of the interaction between myospryn and PRKAR2A.

Induction. Down-regulated in muscle cell lines derived from patients with Duchenne muscular dystrophy (DMD).

RefSeq proteins (1): NP_705838* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001870	B30.2/SPRY	Domain
IPR003877	SPRY_dom	Domain
IPR003961	FN3_dom	Domain
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036116	FN3_sf	Homologous_superfamily
IPR043136	B30.2/SPRY_sf	Homologous_superfamily
IPR050617	E3_ligase_FN3/SPRY	Family

Pfam: PF00622

UniProt features (139 total): compositionally biased region 38, region of interest 33, sequence conflict 29, sequence variant 28, modified residue 5, domain 3, coiled-coil region 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

No AlphaFold model available for Q8N3K9 — AlphaFold DB does not currently provide models for proteins above ~3000 aa.

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 155, 631, 2404, 2813, 3228

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 86 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_DN, TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_DN, RGAGGAARY_PU1_Q6, AP1FJ_Q2, GOCC_M_BAND, LEIN_CEREBELLUM_MARKERS, GOCC_SARCOPLASM, GOCC_A_BAND, WGTTNNNNNAAA_UNKNOWN, TCANNTGAY_SREBP1_01, RICKMAN_HEAD_AND_NECK_CANCER_F, DUTERTRE_ESTRADIOL_RESPONSE_24HR_DN, BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_A, GOCC_SUPRAMOLECULAR_COMPLEX, GOCC_SUPRAMOLECULAR_POLYMER

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (5): nucleus (GO:0005634), cytoplasm (GO:0005737), sarcoplasmic reticulum (GO:0016529), M band (GO:0031430), perinuclear region of cytoplasm (GO:0048471)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
endoplasmic reticulum	1
sarcoplasm	1
A band	1
cytoplasm	1

Protein interactions and networks

STRING

1454 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CMYA5	DTNBP1	Q96EV8	840
CMYA5	PRKAR2A	P13861	835
CMYA5	TTN	Q8WZ42	780
CMYA5	PRKAR1B	P31321	757
CMYA5	CAPN3	P20807	753
CMYA5	ACTN2	P35609	669
CMYA5	DTNA	Q9Y4J8	665
CMYA5	MEF2A	Q02078	605
CMYA5	BBOX1	O75936	602
CMYA5	MYOZ2	Q9NPC6	595
CMYA5	SYNM	O15061	542
CMYA5	DMD	P11532	531
CMYA5	NKAIN4	Q8IVV8	493
CMYA5	PRKACA	P17612	475
CMYA5	PRKACG	P22612	471

IntAct

21 interactions, top by confidence:

A	B	Type	Score
CMYA5	DYSF	psi-mi:“MI:0403”(colocalization)	0.500
DYSF	CMYA5	psi-mi:“MI:2364”(proximity)	0.500
CMYA5	H1-1	psi-mi:“MI:0915”(physical association)	0.400
SIRT1	KPNA3	psi-mi:“MI:0915”(physical association)	0.400
SIRT3		psi-mi:“MI:0915”(physical association)	0.400
HSPB2	CMYA5	psi-mi:“MI:0915”(physical association)	0.370
OCRL	MYO1C	psi-mi:“MI:0914”(association)	0.350
Prdm16	ESYT2	psi-mi:“MI:0914”(association)	0.350
	POLRMT	psi-mi:“MI:0914”(association)	0.350
PSMC4	CMYA5	psi-mi:“MI:0915”(physical association)	0.000
BZW1	CMYA5	psi-mi:“MI:0915”(physical association)	0.000
PKNOX1	CMYA5	psi-mi:“MI:0915”(physical association)	0.000
CAPN3	CMYA5	psi-mi:“MI:0915”(physical association)	0.000
CLIP4	CMYA5	psi-mi:“MI:0915”(physical association)	0.000
CMYA5	CMYA5	psi-mi:“MI:0915”(physical association)	0.000
IL6ST	CMYA5	psi-mi:“MI:0915”(physical association)	0.000
CMYA5	DYSF	psi-mi:“MI:0915”(physical association)	0.000
CMYA5	MYBPC2	psi-mi:“MI:0915”(physical association)	0.000
CMYA5	OPTN	psi-mi:“MI:0915”(physical association)	0.000
SNAPIN	CMYA5	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (38): CMYA5 (Two-hybrid), CMYA5 (Affinity Capture-MS), CMYA5 (Affinity Capture-MS), CMYA5 (Affinity Capture-MS), CMYA5 (Affinity Capture-MS), CMYA5 (Affinity Capture-MS), CMYA5 (Affinity Capture-RNA), CMYA5 (Synthetic Lethality), CMYA5 (Affinity Capture-MS), CMYA5 (Affinity Capture-MS), CMYA5 (Affinity Capture-MS), CMYA5 (Proximity Label-MS), CMYA5 (Two-hybrid), CMYA5 (Two-hybrid), CMYA5 (Two-hybrid)

ESM2 similar proteins: A0A0P0XCU3, A0A1P8BH59, A1YFC1, A1YGK6, A2T7F2, A6NJ88, B7SY83, F1QU13, F4HXQ7, F4ICX9, F4INW9, F4KCE9, O04251, O81472, O96001, P0CV01, P0CV36, P0CV42, P0CV43, P0CV45, P0CV46, P0CV55, P0CV57, P0CV58, P10322, P16531, P48786, Q0DVU4, Q10P83, Q2EI21, Q3URU2, Q5JY77, Q5QNA6, Q5R7U0, Q5SRN2, Q5U4C1, Q5XPK0, Q6K5K2, Q7T2B3, Q8N3K9

Diamond homologs: A0JN74, A1L4K1, A2ABU4, A2ASS6, B1H278, H0UZ81, O00478, P18892, P82456, Q02084, Q13410, Q1XHU0, Q495X7, Q5BN31, Q5D7I0, Q5R7W8, Q5R996, Q5VTT5, Q6MFZ5, Q6UX41, Q6UXE8, Q70KF4, Q7YRV4, Q8BVW3, Q8BZ52, Q8N3K9, Q8VI40, Q8WVV5, Q8WZ42, Q91431, Q96F44, Q96KV6, Q96PL5, Q99PQ2, Q9ESN2, Q9HCM9, Q9JLN5, O00481, O00635, O75679

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

717 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	552
Likely benign	84
Benign	28

Top pathogenic / likely-pathogenic (0)

SpliceAI

2125 predictions. Top by Δscore:

Variant	Effect	Δscore
5:79690040:G:GT	donor_gain	1.0000
5:79690052:TCCAG:T	donor_loss	1.0000
5:79690053:CCAGG:C	donor_loss	1.0000
5:79690054:CAGG:C	donor_loss	1.0000
5:79690055:AGGT:A	donor_loss	1.0000
5:79690056:GGT:G	donor_loss	1.0000
5:79690058:T:G	donor_loss	1.0000
5:79743824:CA:C	acceptor_loss	1.0000
5:79743825:A:AG	acceptor_gain	1.0000
5:79743826:G:GG	acceptor_gain	1.0000
5:79743921:AGG:A	donor_loss	1.0000
5:79743922:GGTA:G	donor_loss	1.0000
5:79743923:G:GA	donor_loss	1.0000
5:79743924:T:A	donor_loss	1.0000
5:79745220:A:AG	acceptor_gain	1.0000
5:79745220:AG:A	acceptor_gain	1.0000
5:79745221:G:GA	acceptor_gain	1.0000
5:79745221:GG:G	acceptor_gain	1.0000
5:79745221:GGA:G	acceptor_gain	1.0000
5:79745221:GGAA:G	acceptor_gain	1.0000
5:79745221:GGAAA:G	acceptor_gain	1.0000
5:79745451:TGACT:T	donor_gain	1.0000
5:79745452:GACT:G	donor_gain	1.0000
5:79745452:GACTG:G	donor_gain	1.0000
5:79745453:ACT:A	donor_gain	1.0000
5:79745453:ACTGT:A	donor_loss	1.0000
5:79745454:CT:C	donor_gain	1.0000
5:79745454:CTG:C	donor_loss	1.0000
5:79745455:TGT:T	donor_loss	1.0000
5:79745456:G:GG	donor_gain	1.0000

AlphaMissense

26516 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:79763127:T:A	W3825R	0.999
5:79763127:T:C	W3825R	0.999
5:79758821:T:A	W3727R	0.998
5:79758821:T:C	W3727R	0.998
5:79793486:T:A	W3947R	0.998
5:79793486:T:C	W3947R	0.998
5:79758816:T:A	V3725D	0.997
5:79761924:A:C	S3792R	0.997
5:79761926:C:A	S3792R	0.997
5:79761926:C:G	S3792R	0.997
5:79761933:A:C	S3795R	0.997
5:79761935:T:A	S3795R	0.997
5:79761935:T:G	S3795R	0.997
5:79789077:A:C	S3888R	0.997
5:79789079:T:A	S3888R	0.997
5:79789079:T:G	S3888R	0.997
5:79758861:T:A	V3740D	0.996
5:79793488:G:C	W3947C	0.996
5:79793488:G:T	W3947C	0.996
5:79729495:T:C	F244L	0.995
5:79729496:T:C	F244S	0.995
5:79729497:T:A	F244L	0.995
5:79729497:T:G	F244L	0.995
5:79763116:C:A	A3821D	0.995
5:79789068:A:C	S3885R	0.995
5:79789070:T:A	S3885R	0.995
5:79789070:T:G	S3885R	0.995
5:79790979:T:C	F3900S	0.995
5:79799471:T:C	F4022S	0.995
5:79729451:T:G	I229S	0.994

dbSNP variants (sampled 300 via entrez): RS1000011623 (5:79720369 G>T), RS1000071855 (5:79722036 A>G,T), RS1000080998 (5:79771369 G>C), RS1000111830 (5:79726960 G>C,T), RS1000150111 (5:79767319 C>G), RS1000154695 (5:79743148 C>G,T), RS1000179991 (5:79703002 C>G), RS1000182912 (5:79772627 C>T), RS1000192286 (5:79746655 T>C), RS1000195385 (5:79698186 T>A,C), RS1000195618 (5:79797041 A>G), RS1000242730 (5:79749796 G>A), RS1000284559 (5:79771099 T>G), RS1000333028 (5:79755882 A>G), RS1000334192 (5:79711002 A>G,T)

Disease associations

OMIM: gene MIM:612193 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST001732_1	Obesity	1.000000e-06
GCST002671_8	Toenail selenium levels	6.000000e-06
GCST006364_2	Hepatitis B surface antigen seroclearance in chronic hepatitis B infection	4.000000e-06
GCST009378_14	Bone mineral content	5.000000e-06
GCST009378_22	Bone mineral content	8.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0009345	Hepatitis B virus surface antigen seropositivity
EFO:0007621	bone mineral content measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

13 total (human), top 13 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Nickel	decreases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
sodium arsenite	affects expression	1
Amiodarone	increases expression	1
Benzo(a)pyrene	decreases methylation	1
Cuprizone	affects cotreatment, decreases expression	1
Doxorubicin	decreases expression	1
Estradiol	affects cotreatment, decreases expression	1
Haloperidol	affects cotreatment, decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Triclosan	decreases expression	1
Copper Sulfate	decreases expression	1
S-Nitrosoglutathione	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.